2 ms·
> In early January 2022, Amylyx has submitted a Marketing Authorization Application (MAA) for Relyvrio/Albrioza to the European Medicines Agency (EMA). I hope
by rawbert 4y ago
> In early January 2022, Amylyx has submitted a Marketing Authorization Application (MAA) for Relyvrio/Albrioza to the European Medicines Agency (EMA).
I hope this wont end the same way like edaravone.